Aclarion Grants 17,000-Share Option at $3.20 to Commercial Director
ACON•Aclarion’s compensation committee granted its new Commercial Director an inducement option for 17,000 shares at $3.20 per share on May 5, 2026. The option vests over four years with a 10-year term and underscores Nociscan’s triple-digit utilization growth in the Western U.S.
1. Inducement Grant Details
On May 5, 2026, Aclarion’s compensation committee approved an inducement stock option grant for Daniel Keefe, its newly hired Commercial Director for the Western U.S. The grant consists of options to purchase 17,000 shares of common stock at an exercise price of $3.20 per share, matching the closing market price on the grant date.
2. Vesting Schedule and Terms
One-quarter of the granted options vests on the one-year anniversary of the vesting commencement date, with the remaining options vesting in equal monthly installments over the following three years, contingent on continued employment. The options carry a 10-year term and are governed by Aclarion’s inducement stock option agreement.
3. Team Expansion Reflects Utilization Growth
The new hire and option grant coincide with triple-digit growth in Nociscan utilization, signaling rising adoption of Aclarion’s biomarker-based imaging platform. Strengthening the Western U.S. commercial team aims to capitalize on increasing physician demand and support further revenue expansion.
